CompletedNot Applicable

CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis

Germany112 participantsStarted 2021-04-01

Plain-language summary

The study aims to test the diagnostic accuracy of T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that T1 mapping in older patients with symptomatic heart failure, increased LV wall thickness and elevated cardiac biomarkers is non-inferior to the reference method to diagnose cardiac amyloidosis (CA). As secondary measure, a web-based ATTR probability estimator for the diagnosis of CA will be evaluated.

Who can participate

Age range60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 60 years * Symptomatic heart failure (NYHA II-IV) with LVEF ≥40% * Increased LV wall thickness (≥12mm end-diastolic) * NT-proBNP ≥1000pg/mL * Elevated hs-troponin T ≥14ng/L Exclusion Criteria: * Contraindications for CMR * Acute myocarditis * Acute myocardial infarction \<1 month * Severe aortic stenosis and RAISE score \< 2 points

What they're measuring

Diagnostic accuracy of T1 mapping for diagnosis of CA

Timeframe: up to 7 days

Trial details

NCT IDNCT04862273

SponsorUniversity of Leipzig

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-01

View on ClinicalTrials.gov More Heart Failure NYHA Class II trials